Nasdaq determines POMDOCTOR LIMITED securities subject to delisting
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
What happened
POMDOCTOR LIMITED received a determination letter from Nasdaq's Listing Qualifications Department on October 6, 2026, regarding its minimum bid price requirement. The company's American depositary shares were below $1.00 per share for 30 consecutive business days, spanning August 24, 2026, through October 5, 2026. Because POMDOCTOR LIMITED completed a 1-for-18 reverse stock split on June 22, 2026, it is ineligible for the standard compliance period, meaning its securities are subject to delisting unless an appeal is filed.
Why it matters
The determination means that POMDOCTOR LIMITED's securities face suspension from trading at the opening of business unless the company successfully appeals the Staff's decision. Failure to appeal will result in the securities being delisted from The Nasdaq Global Market.
Who's involved
- NasdaqThe Nasdaq Stock Market LLC, which issued the determination letter regarding minimum bid price compliance.
How it developed
Newest first. Tap a step to see who reported it.POMDOCTOR LIMITED regained compliance with Nasdaq's minimum bid price requirement.1 source
POMDOCTOR LIMITED was threatened with delisting from Nasdaq due to low bid price.1 source
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Nasdaq entered correction territory on November 6, 2026, amid broader market fears.
- Nasdaq determined to delist Robot Consulting Co., Ltd.'s ADSs and filed the necessary forms with the SEC.
- Global sell-off caused Nasdaq to sink sharply amid threats to expand military strikes against Iran.
- Donald Trump blamed voters for the recent market drop.